Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:IOVA NASDAQ:LXEO NASDAQ:SAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.79-1.3%$7.23$5.90▼$34.11$568.59M2.171.49 million shs1.28 million shsIOVAIovance Biotherapeutics$1.87-3.1%$2.01$1.64▼$12.51$624.45M0.859.12 million shs6.77 million shsLXEOLexeo Therapeutics$4.47-2.6%$3.65$1.45▼$19.50$148.40M1.32543,351 shs139,727 shsSAGESage Therapeutics$9.27+0.7%$7.66$4.62▼$13.47$580.49M0.291.32 million shs3.06 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-4.13%-0.01%+0.90%+13.53%-69.94%IOVAIovance Biotherapeutics-3.02%+10.03%-18.91%-41.52%-75.19%LXEOLexeo Therapeutics-0.22%+3.61%-0.43%+131.82%-72.08%SAGESage Therapeutics+0.11%+0.16%+31.76%+28.63%-16.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas3.572 of 5 stars4.32.00.00.01.82.51.3IOVAIovance Biotherapeutics4.7499 of 5 stars4.31.00.04.22.34.21.3LXEOLexeo Therapeutics2.4932 of 5 stars3.51.00.00.02.32.50.6SAGESage Therapeutics3.2394 of 5 stars2.02.00.04.12.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.55Moderate Buy$20.29160.46% UpsideIOVAIovance Biotherapeutics 2.50Moderate Buy$12.22553.59% UpsideLXEOLexeo Therapeutics 3.00Buy$16.60271.36% UpsideSAGESage Therapeutics 1.94Reduce$8.75-5.65% DownsideCurrent Analyst Ratings BreakdownLatest LXEO, IOVA, ARVN, and SAGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025SAGESage TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$12.00 ➝ $9.206/20/2025SAGESage TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.006/17/2025SAGESage TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$9.00 ➝ $8.506/17/2025SAGESage TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHold ➝ Hold$8.00 ➝ $9.006/17/2025SAGESage TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$12.006/17/2025SAGESage TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$8.00 ➝ $8.506/16/2025SAGESage TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold6/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.006/2/2025ARVNArvinasLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.006/1/2025ARVNArvinasLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/30/2025LXEOLexeo TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $10.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$263.40M2.16N/AN/A$8.17 per share0.95IOVAIovance Biotherapeutics$164.07M3.81N/AN/A$2.33 per share0.80LXEOLexeo Therapeutics$650K228.31N/AN/A$3.53 per share1.27SAGESage Therapeutics$41.24M14.08N/AN/A$7.60 per share1.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%7/29/2025 (Estimated)IOVAIovance Biotherapeutics-$372.18M-$1.24N/AN/AN/A-176.49%-49.71%-39.18%8/6/2025 (Estimated)LXEOLexeo Therapeutics-$98.33M-$3.30N/AN/AN/AN/A-85.86%-68.48%8/11/2025 (Estimated)SAGESage Therapeutics-$400.67M-$5.80N/AN/AN/A-747.63%-68.99%-60.67%7/30/2025 (Estimated)Latest LXEO, IOVA, ARVN, and SAGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025SAGESage Therapeutics-$0.96N/AN/AN/A$16.69 millionN/A7/29/2025Q2 2025ARVNArvinas-$0.87N/AN/AN/A$34.42 millionN/A5/12/2025Q1 2025LXEOLexeo Therapeutics-$0.80-$0.99-$0.19-$0.99N/AN/A5/8/2025Q1 2025IOVAIovance Biotherapeutics-$0.25-$0.36-$0.11-$0.36$83.40 million$49.32 million5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/A4/29/2025Q1 2025SAGESage Therapeutics-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.584.58IOVAIovance BiotherapeuticsN/A4.183.64LXEOLexeo Therapeutics0.013.423.42SAGESage TherapeuticsN/A9.139.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%IOVAIovance Biotherapeutics77.03%LXEOLexeo Therapeutics60.67%SAGESage Therapeutics99.22%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%IOVAIovance Biotherapeutics10.30%LXEOLexeo Therapeutics5.30%SAGESage Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42072.99 million69.54 millionOptionableIOVAIovance Biotherapeutics500333.93 million299.54 millionOptionableLXEOLexeo Therapeutics5833.20 million31.44 millionNot OptionableSAGESage Therapeutics69062.62 million59.18 millionOptionableLXEO, IOVA, ARVN, and SAGE HeadlinesRecent News About These CompaniesSage Therapeutics (NASDAQ:SAGE) Stock Rating Lowered by ScotiabankJuly 11 at 2:11 AM | americanbankingnews.comBeyond The Numbers: 6 Analysts Discuss Sage Therapeutics StockJuly 9 at 8:16 PM | nasdaq.comScotiabank Downgrades Sage Therapeutics (SAGE)July 9 at 3:48 AM | msn.comScotiabank Reiterates "Sector Perform" Rating for Sage Therapeutics (NASDAQ:SAGE)July 8 at 8:40 AM | marketbeat.comWealth Enhancement Advisory Services LLC Takes $347,000 Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)July 8 at 3:13 AM | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of "Hold" from AnalystsJuly 6, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Share Price Passes Above Two Hundred Day Moving Average - Here's WhyJuly 4, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Shares Pass Above 50 Day Moving Average - Here's WhyJuly 4, 2025 | marketbeat.comRx Rundown: AbbVie, Healthline, Beckley Psytech and moreJuly 3, 2025 | mmm-online.comMSage’s Search for Lifeline Ran Into Defiant Biogen CEOJuly 3, 2025 | biospace.comBM&A ramped up in June, with blueBird, Sage and Snyk tie-upsJuly 2, 2025 | bizjournals.comBoston-area pharma company to lay off entire 300-person staff after saleJuly 1, 2025 | msn.com$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. (NASDAQ: SAGE)July 1, 2025 | globenewswire.comWhat Makes Sage Therapeutics (SAGE) a New Buy StockJuly 1, 2025 | zacks.comSage Therapeutics cuts most of its workforce following acquisitionJuly 1, 2025 | statnews.comSSage lays off entire staff of 338 amid takeover by SupernusJuly 1, 2025 | fiercepharma.comFThis common kitchen herb ingredient could help target or slow Alzheimer’sJune 29, 2025 | msn.comSage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout TermsJune 23, 2025 | msn.comPhathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate SecretaryJune 23, 2025 | globenewswire.comSage Therapeutics price target lowered to $8.50 from $11 at JPMorganJune 22, 2025 | msn.comSage Therapeutics (NASDAQ:SAGE) Given New $9.00 Price Target at Robert W. BairdJune 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingBy Chris Markoch | June 29, 2025View 3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingLXEO, IOVA, ARVN, and SAGE Company DescriptionsArvinas NASDAQ:ARVN$7.79 -0.10 (-1.27%) Closing price 04:00 PM EasternExtended Trading$7.78 0.00 (-0.06%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Iovance Biotherapeutics NASDAQ:IOVA$1.87 -0.06 (-3.11%) Closing price 04:00 PM EasternExtended Trading$1.89 +0.02 (+1.07%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Lexeo Therapeutics NASDAQ:LXEO$4.47 -0.12 (-2.61%) Closing price 04:00 PM EasternExtended Trading$4.48 +0.01 (+0.22%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Sage Therapeutics NASDAQ:SAGE$9.27 +0.06 (+0.65%) Closing price 04:00 PM EasternExtended Trading$9.24 -0.03 (-0.27%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
